These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32223036)

  • 21. Multiparameter flow cytometry applications in the diagnosis of mixed phenotype acute leukemia.
    Porwit A; Béné MC
    Cytometry B Clin Cytom; 2019 May; 96(3):183-194. PubMed ID: 31033213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First report of familial mixed phenotype acute leukemia: shared clinical characteristics, Philadelphia translocation, and germline variants.
    Shiozawa Y; Fujita S; Nannya Y; Ogawa S; Nomura N; Kiguchi T; Sezaki N; Kudo H; Toyama T
    Int J Hematol; 2024 Apr; 119(4):465-471. PubMed ID: 38424413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes in patients with mixed phenotype acute leukemia in Morocco.
    Bachir F; Zerrouk J; Howard SC; Graoui O; Lahjouji A; Hessissen L; Bennani S; Quessar A; El Aouad R
    J Pediatr Hematol Oncol; 2014 Aug; 36(6):e392-7. PubMed ID: 23619119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flow cytometric analysis of Mixed phenotype acute leukemia: experience from a tertiary oncology center.
    Sukumaran R; Nair RA; Jacob PM; Nair Anila KA; Prem S; Binitha R; Kusumakumary P
    Indian J Pathol Microbiol; 2015; 58(2):181-6. PubMed ID: 25885130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial.
    Hyakuna N; Hashii Y; Ishida H; Umeda K; Takahashi Y; Nagasawa M; Yabe H; Nakazawa Y; Koh K; Goto H; Fujisaki H; Matsumoto K; Kakuda H; Yano M; Tawa A; Tomizawa D; Taga T; Adachi S; Kato K
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27875. PubMed ID: 31309713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosing and treating mixed phenotype acute leukemia: a multicenter 10-year experience in México.
    Deffis-Court M; Alvarado-Ibarra M; Ruiz-Argüelles GJ; Rosas-López A; Barrera-Lumbreras G; Aguayo-González A; López-Karpovitch X; López-Hernández M; Velázquez-Sánchez de Cima S; Zamora-Ortiz G; Crespo-Solís E
    Ann Hematol; 2014 Apr; 93(4):595-601. PubMed ID: 24146232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical Effect and Safety of CCLG-ALL 2008 (high risk group) Protocol in the Treatment of Childhood Mixed Phenotype Acute Leukemia].
    Zheng YZ; LE SH; Zheng H; Hua XL; Chen ZS; Zheng L; Chen C; Li M; Cai CX; Yang JH; Chen YQ; Gao QL; Chen YY; Pan LL; Li J; Hu JD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):49-55. PubMed ID: 33554796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia.
    Munker R; Brazauskas R; Wang HL; de Lima M; Khoury HJ; Gale RP; Maziarz RT; Sandmaier BM; Weisdorf D; Saber W;
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1024-1029. PubMed ID: 26903380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mixed-Phenotype Acute Leukemia: Diagnostic Criteria and Pitfalls.
    Charles NJ; Boyer DF
    Arch Pathol Lab Med; 2017 Nov; 141(11):1462-1468. PubMed ID: 29072953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mixed phenotype acute leukemia.
    Ye Z; Wang S
    Chin Med J (Engl); 2014; 127(16):2999-3003. PubMed ID: 25131241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leukemia With
    Lin N; Yan X; Cai D; Wang L
    Front Oncol; 2021; 11():709036. PubMed ID: 34395283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of EGIL1998 and WHO2008 criteria for the diagnosis of mixed phenotype acute leukemia].
    Ye L; Lin D; Mi YC; Zhang J; Wang Y; Wang HJ; Wei H; Liu BC; Zhou CL; Li W; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):286-90. PubMed ID: 22781719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study.
    Duong VH; Begna KH; Kashanian S; Sweet K; Wang ES; Caddell R; Shafer DA; Singh ZN; Baer MR; Al-Kali A
    Ann Hematol; 2020 Sep; 99(9):2119-2124. PubMed ID: 32676733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mixed-phenotype acute leukemia characteristics: first report from Iran.
    Poopak B; Khosravi A; Bahoush-Mehdiabadi G; Madani T; Khodadi E; Farahani Z; Vahedi AA; Khosravipour G; Poopak P; Poopak AH
    Clin Exp Med; 2018 Nov; 18(4):513-521. PubMed ID: 30019150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].
    Gu B; Chen GH; Shen HJ; Ma X; Fu CC; Han Y; Tang XW; Miao M; Qiu HY; Sun AN; Wu DP
    Zhonghua Nei Ke Za Zhi; 2016 Apr; 55(4):293-7. PubMed ID: 27030618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinico-hematological profile in biphenotypic acute leukemia.
    Gujral S; Polampalli S; Badrinath Y; Kumar A; Subramanian PG; Raje G; Amare P; Arora B; Banavali SD; Nair CN
    Indian J Cancer; 2009; 46(2):160-8. PubMed ID: 19346652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A hybrid protocol CLAG-M, a possible player for the first-line therapy of patients with mixed phenotype acute leukemia. A Polish Adult Leukemia Group experience.
    Karasek M; Armatys A; Skarupski M; Bołkun Ł; Budziszewska K; Drozd-Sokołowska J; Zarzycka E; Mensah-Glanowska P; Gajewska M; Hałka J; Kopacz A; Prejzer W; Chyrko O; Wróbel T; Wierzbowska A; Sobas M
    Front Oncol; 2024; 14():1395992. PubMed ID: 38835383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful acute lymphoblastic leukemia-type therapy in two children with mixed-phenotype acute leukemia.
    Otsubo K; Yabe M; Yabe H; Fukumura A; Morimoto T; Kato M; Mochizuki H
    Pediatr Int; 2016 Oct; 58(10):1072-1076. PubMed ID: 27577674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved survival outcome of childhood acute myeloid leukemia with intensified chemotherapy in Chinese children.
    Zhai XW; Cheng FW; Lee V; Leung WK; Ng MH; Tsang KS; Shing MK; Li CK
    Pediatr Hematol Oncol; 2011 May; 28(4):269-78. PubMed ID: 21345081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.